Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer

被引：0
|
作者：
Spring, L. M. [1 ,2 ]
Han, H. [3 ]
Hamilton, E. [4 ]
Irie, H. [5 ]
Santa-Maria, C. A. [6 ]
Reeves, J. [7 ]
Pan, P. [8 ]
Shan, M. [8 ]
Tang, Y. [8 ]
Graham, J. R. [8 ]
Hazard, S. [8 ]
Ellisen, L. W. [1 ,2 ]
Isakoff, S. J. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Tampa, FL USA
[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Sarah Cannon Res Inst, Florida Canc Specialists South, Ft Myers, FL USA
[8] GSK, Waltham, MA USA
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P095
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [31] Niraparib efficacy and safety in patients with BRCA-mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials
    Banerjee, Ashish
    Gonzalez-Martin, Antonio
    Matulonis, Ursula
    Korach, Jacob
    Mirza, Mansoor R.
    Moore, Kathleen
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 116 - 117
  • [32] Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer
    Han, H.
    Hamilton, E.
    Irie, H.
    Isakoff, S.
    Jelovac, D.
    Liem, A.
    Liu, M. C.
    Milillo, A.
    Nangia, J.
    Page, D.
    Reeves, J.
    Santa-Maria, C.
    Duncan, M.
    Graham, J. R.
    Chen, J.
    Dezube, B. J.
    Spring, L.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
    Gelmon, Karen A.
    Fasching, Peter A.
    Couch, Fergus J.
    Balmana, Judith
    Delaloge, Suzette
    Labidi-Galy, Intidhar
    Bennett, James
    McCutcheon, Susan
    Walker, Graham
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 68 - 77
  • [34] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 63 - 68
  • [35] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [36] NEW TREATMENT FOR BRCA-MUTATED METASTATIC BREAST CANCER
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2018, 118 (05) : 21 - 23
  • [37] Niraparib efficacy and safety in patients with BRCA-mutated (BRCAm) ovarian cancer: results from three phase 3 niraparib trials
    Gonzalez-Martin, Antonio
    Grabowski, Jacek
    Matulonis, Ursula
    Korach, Jacob
    Mirza, Mansoor
    Moore, Kathleen
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 120 - 120
  • [38] Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
    Pan, Junjie
    Ren, Ning
    Ren, Lanqi
    Yang, YiBei
    Xu, Qiaoping
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [39] Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
    Roudini, Kamran
    Mirzania, Mehrzad
    Yavari, Tahereh
    Seyyedsalehi, Monireh Sadat
    Nahvijou, Azin
    Zebardast, Jayran
    Saadat, Mina
    Khajeh-Mehrizi, Ahmad
    ARCHIVES OF IRANIAN MEDICINE, 2024, 27 (04) : 206 - 215
  • [40] PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.
    Poggio, Francesca
    Bruzzone, Marco
    Ceppi, Marcello
    Conte, Benedetta
    Martel, Samuel
    Maurer, Christian
    Tagliamento, Marco
    Viglietti, Giulia
    Del Mastro, Lucia
    De Azambuja, Evandro
    Lambertini, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345